Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
0.904
+0.010 (1.13%)
Jun 21, 2024, 2:15 PM EDT - Market open

Lineage Cell Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 1996
Net Income
-21.49-26.27-43.02-20.65-11.71
Upgrade
Depreciation & Amortization
0.690.730.872.113.13
Upgrade
Share-Based Compensation
4.644.293.722.353.58
Upgrade
Other Operating Activities
-12.4122.3214.86-3.56-26.95
Upgrade
Operating Cash Flow
-28.571.06-23.56-19.75-31.95
Upgrade
Capital Expenditures
-0.67-0.41-0.34-0.04-0.36
Upgrade
Acquisitions
0010.0913.0617.33
Upgrade
Change in Investments
47.12-45.75000
Upgrade
Other Investing Activities
---0.02-0.02
Upgrade
Investing Cash Flow
46.45-46.169.7513.0416.96
Upgrade
Share Issuance / Repurchase
6.590.1330.815.1-0.01
Upgrade
Debt Issued / Paid
-0.05-0.03-0.0225.12-0.1
Upgrade
Other Financing Activities
-0.111.536.14-0.360.72
Upgrade
Financing Cash Flow
6.421.6336.9329.870.62
Upgrade
Exchange Rate Effect
-0.25-0.87-0.02-0.060.07
Upgrade
Net Cash Flow
24.06-44.3423.0923.09-14.3
Upgrade
Free Cash Flow
-29.240.65-23.9-19.79-32.31
Upgrade
Free Cash Flow Margin
-326.89%4.39%-550.59%-1084.01%-919.06%
Upgrade
Free Cash Flow Per Share
-0.170.00-0.14-0.13-0.22
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).